<DOC>
	<DOC>NCT01439347</DOC>
	<brief_summary>A phase 3 study in the treatment of subjects &gt;or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).</brief_summary>
	<brief_title>A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL</brief_title>
	<detailed_description>A phase 3, multicenter, randomized study to evaluate the substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for standard Vincristine Sulfate Injection (VSI) in the induction, intensification, and maintenance phases of combination chemotherapy in the treatment of subjects &gt;or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Have provided written, signed, and dated informed consent to participate in the study, in accordance with the ICH GCP Guideline E6 and all applicable local regulations.Are age &gt;or=60 years (at the time of providing informed consent). Have newly diagnosed, histologically proven, untreated Philadelphia chromosomenegative (Ph) ALL, with &gt;or= 5% bone marrow blasts. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 02. Have a life expectancy &gt;or= 3 months. Have renal and liver function as defined below within 14 days, inclusive, prior to study enrollment, unless the abnormality is considered attributable to leukemia: Total bilirubin ≤ 2.0 x the upper limit of normal (ULN), unless the subject has a known diagnosis of Gilbert's disease Aspartate transaminase (AST, SGOT) or alanine transaminase (ALT, SGPT) ≤ 3 x ULN Serum creatinine ≤ 1.5 x ULN. Not have had major surgery within 4 weeks before the planned start of treatment. If female, are postmenopausal, surgically sterilized, or willing to use acceptable methods of birth control (eg, hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) from the screening visit through 30 days after the last dose of any protocol defined chemotherapeutic agents. If male and sexually active with a partner of childbearing potential, agree to use an acceptable barrier method for contraception from the screening visit through 30 days after the last dose of any protocol defined chemotherapeutic agents. Have the ability and willingness to fully comply with study procedures and restrictions. Has had prior systemic chemotherapy (for ALL or other malignancy). Has had prior vincristine for any reason. Is planning to undergo stem cell transplantation (SCT) as any part of firstline therapy for ALL. Has Burkitt's lymphoma/leukemia. Has Philadelphia chromosomepositive (Ph+) ALL and/or BCR/ABL rearrangements documented by fluorescent insitu hybridization (FISH), cytogenetics, or polymerase chain reaction (PCR). Has active central nervous system (CNS) disease. Has ongoing neuropathy of any etiology &gt; Grade 1. Has a history of persistent active neurologic disorders including demyelinating form of CharcotMarieTooth syndrome, acquired demyelinating disorders, and other demyelinating conditions. Prior hydroxyurea (Hydrea®) for the management of any condition other than leukocytosis or prior hydroxyurea of &gt;7 days duration for the management of leukocytosis (hydroxyurea for the management of leukocytosis must be planned to be tapered off before or on Day 5 of Induction). Has received prior steroids within 7 days before beginning protocolspecified Induction therapy for reasons other than leukocytosis (steroids for the management of leukocytosis are allowed but must be planned to be tapered off before or on Day 5 of Induction). Has an active serious infection not controlled by oral or IV antibiotics or antifungals. Has received any investigational therapy within 28 days before beginning any protocoldefined chemotherapeutic treatment.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Marqibo</keyword>
	<keyword>HALLMARQ</keyword>
	<keyword>leukemia</keyword>
	<keyword>front-line</keyword>
	<keyword>ALL</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
</DOC>